Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7490235 | 0.82 | TSHR (0.37) | PPARDTSHRSMN1; SMN2TP53TDP1 | |
| SCHEMBL6579016 | 0.81 | TSHR (0.40) | PPARDTSHRSMN1; SMN2TP53TDP1 | |
| SCHEMBL98778 | 0.78 | PPARD (0.38) | PPARDTSHRSMN1; SMN2TP53TDP1 | |
| SCHEMBL98777 | 0.77 | TSHR (0.40) | PPARDTSHRSMN1; SMN2TP53TDP1 | |
| SCHEMBL11330355 | 0.77 | GAA (0.32) | TSHRSMN1; SMN2 | |
| SCHEMBL2640685 | 0.76 | LMNA (0.38) | TSHRALDH1A1 | |
| SCHEMBL4637563 | 0.74 | PPARD (0.35) | PPARDTSHRSMN1; SMN2TP53TDP1 | |
| SCHEMBL4550022 | 0.73 | PPARD (0.38) | PPARDTSHRSMN1; SMN2TP53TDP1 | |
| SCHEMBL6623038 | 0.73 | PPARD (0.38) | PPARDTSHRTP53TDP1CA12 | |
| SCHEMBL9115357 | 0.73 | TSHR (0.46) | PPARDTSHRTP53TDP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758402-B9 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2758402-B1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2968336-A2 | COMBINATION OF AN EGFR T790M INHIBITOR AND AN EGFR INHIBITOR FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | Pfizer Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150203502-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2015-07-23 | — | — | US | disclosed |
| US-9040547-B2 | Pyrrolopyrimidine and purine derivatives | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| WO-2014140989-A2 | COMBINATION OF AN EGFR T790M INHIBITOR AND AN EGFR INHIBITOR FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | PFIZER INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2758402-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | Pfizer Inc (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. | 2013-03-28 | — | — | US | disclosed |
| WO-2013042006-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-7067511-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-7049311-B1 | Pyrrolbenzodiazepines | SPIROGEN LIMITED (GB) | 2006-05-23 | — | — | US | disclosed |
| EP-1109812-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2005-05-04 | — | — | EP | disclosed |
| EP-1413582-A1 | Dimeric pyrrolobenzodiazepines | Spirogen Limited (GB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030120069-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-06-26 | — | — | US | disclosed |
| EP-1193270-A2 | Pyrrolobenzodiazepines | Spirogen Limited (GB) | 2002-04-03 | — | — | EP | disclosed |
| EP-1109812-A2 | PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012508-A2 | PYRROLBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | TYMP, DPYD, TYMS | PPARD 3175/4885TSHR 1585/4885SMN1; SMN2 2215/4885 |
| US-20150203502-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | TYMP, DPYD, TYMS | PPARD 3175/4885TSHR 1585/4885SMN1; SMN2 2215/4885 |
| US-20030120069-A1 | Pyrrolobenzodiazepines | CNR1, CBX2, CNR2 | PPARD 2971/4885TSHR 765/4885SMN1; SMN2 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.